Skip to main content
SpringerLink
Log in

The Role of Radiation in Urological Malignancies

  • Chapter
  • First Online:
Radiation Therapy for Pelvic Malignancy and its Consequences

  • 990 Accesses

Abstract

Radiation therapy (RT) is a vital component of treatment for many urologic malignancies including prostate cancer, where advancements in RT technique have improved outcomes without adding toxicity. In bladder cancers, use of concurrent chemoradiation therapy and surgery for salvage has yielded survival equivalent to up-front cystectomy with preservation of the bladder. In patients with stage I–II testicular seminomas, RT utilization has been refined to limit unnecessary exposure. The role of RT is not well defined in the management of penile and urethral cancers; however, the literature supports its use as an organ-preserving treatment approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA (a cancer journal for clinicians). 2014;64(1):9–29.

    PubMed  Google Scholar 

  2. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  3. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013;11(12):1471–9.

    CAS  PubMed  Google Scholar 

  4. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28(6):1069–74.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87.

    Article  PubMed  Google Scholar 

  6. Lawton CA, DeSilvio M, Roach M, 3rd, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69(3):646–55.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Terakedis BE, Rossi PJ, Liauw SL, Johnstone PA, Jani AB. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol. 2010;33(6):619–23.

    Article  PubMed  Google Scholar 

  8. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141–9.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–8.

    Article  PubMed  Google Scholar 

  10. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.

    Article  PubMed  Google Scholar 

  11. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.

    Article  PubMed  Google Scholar 

  12. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–9.

    Article  CAS  PubMed  Google Scholar 

  13. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124–9.

    Article  PubMed  Google Scholar 

  14. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(3):685–91.

    Article  PubMed  Google Scholar 

  15. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686–92.

    Article  PubMed  Google Scholar 

  17. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6–13.

    Article  PubMed  Google Scholar 

  18. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010;76(1):50–6.

    Article  PubMed  Google Scholar 

  21. Hinnen KA, Battermann JJ, van Roermund JG, Moerland MA, Jurgenliemk-Schulz IM, Frank SJ, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;76(5):1433–8.

    Article  PubMed  Google Scholar 

  22. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, et al. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014;13(2):157–62.

    Article  PubMed  Google Scholar 

  23. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.

    Article  PubMed  Google Scholar 

  24. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–35.

    Article  CAS  PubMed  Google Scholar 

  25. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–30.

    Article  PubMed  Google Scholar 

  26. Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology. 2010;76(5):1169–74.

    Article  PubMed  Google Scholar 

  27. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190(2):441–9.

    Article  PubMed  Google Scholar 

  28. Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, Trabulsi EJ, et al. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(2):e233–8.

    Article  PubMed  Google Scholar 

  29. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013;63(5):823–9.

    Article  PubMed  Google Scholar 

  30. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  CAS  PubMed  Google Scholar 

  31. Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8.

    Article  PubMed  Google Scholar 

  32. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–44.

    Article  PubMed  Google Scholar 

  33. Kozak KR, Hamidi M, Manning M, Moody JS. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(2):e197–e204.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):326–31.

    Article  PubMed  Google Scholar 

  35. Osswald M, Harlan LC, Penson D, Stevens JL, Clegg LX. Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol. 2009;27(6):604–10.

    Article  PubMed Central  PubMed  Google Scholar 

  36. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. (official journal of the American Society of Clinical Oncology). 2007;25(28):4370–8.

    Article  PubMed  Google Scholar 

  37. Thong AE, Lichtensztajn DY, Almario L, Ingels A, Gomez SL, Gonzalgo ML. Stage I testicular seminoma: a SEER analysis of contemporary adjuvant radiotherapy trends. J Urol. 2013;190(4):1240–4.

    Article  PubMed  Google Scholar 

  38. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146.

    CAS  PubMed  Google Scholar 

  39. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200–8.

    Article  PubMed  Google Scholar 

  40. Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology. 2006;68(6):1164–8.

    Article  PubMed  Google Scholar 

  41. Rabbani F. Prognostic factors in male urethral cancer. Cancer. 2011;117(11):2426–34.

    Article  PubMed  Google Scholar 

  42. Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Male urethral carcinoma: analysis of treatment outcome. Urology. 1999;53(6):1126–32.

    Article  CAS  PubMed  Google Scholar 

  43. Cohen MS, Triaca V, Billmeyer B, Hanley RS, Girshovich L, Shuster T, et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol. 2008;179(2):536–41; discussion 41.

    Article  CAS  PubMed  Google Scholar 

  44. Grigsby PW. Carcinoma of the urethra in women. Int J Radiat Oncol Biol Phys. 1998;41(3):535–41.

    Article  CAS  PubMed  Google Scholar 

  45. Garden AS, Zagars GK, Delclos L. Primary carcinoma of the female urethra. Results of radiation therapy. Cancer. 1993;71(10):3102–8.

    Article  CAS  PubMed  Google Scholar 

  46. Milosevic MF, Warde PR, Banerjee D, Gospodarowicz MK, McLean M, Catton PA, et al. Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiother Oncol. (journal of the European Society for Therapeutic Radiology and. the International Society for Cellular). 2000;56(1):29–35.

    Article  CAS  PubMed  Google Scholar 

  47. Burt LM, Shrieve DC, Tward JD. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys. 2014;88(1):94–100.

    Article  PubMed  Google Scholar 

  48. Ozsahin M, Jichlinski P, Weber DC, Azria D, Zimmermann M, Guillou L, et al. Treatment of penile carcinoma: to cut or not to cut? Int J Radiat Oncol Biol Phys. 2006;66(3):674–9.

    Article  PubMed  Google Scholar 

  49. Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol. 2009;27(2):189–96.

    Article  PubMed  Google Scholar 

  50. Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2011;186(2):524–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 250 E. Superior St. LC-2102, 60611, Chicago, IL, USA

    Eric D. Donnelly MD & Bryan David Macrie MD

Authors
  1. Eric D. Donnelly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryan David Macrie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric D. Donnelly MD .

Editor information

Editors and Affiliations

  1. University of Chicago Medical School, NorthShore University Health System, Highland Park, Illinois, USA

    Eli Daniel Ehrenpreis

  2. University of Chicago Pritzker School of Medicine, NorthShore University Health System, Highland Park, Illinois, USA

    R de W Marsh

  3. Department of Radiation Oncology, Stritch School of Medicine, Loyola University, Chicago, Illinois, USA

    William Small Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Donnelly, E., David Macrie, B. (2015). The Role of Radiation in Urological Malignancies. In: Ehrenpreis, E., Marsh, R., Small Jr., W. (eds) Radiation Therapy for Pelvic Malignancy and its Consequences. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2217-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2217-8_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2216-1

  • Online ISBN: 978-1-4939-2217-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation